OKYO PHARMA LTD SP.ADR/65 (F:OK10) — Stock Price
OKYO PHARMA LTD SP.ADR/65 (F:OK10) is currently trading at €1.36 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €1.36 and €1.36. This page tracks OKYO PHARMA LTD SP.ADR/65's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see OKYO PHARMA LTD SP.ADR/65 (OK10) total market value.
OKYO PHARMA LTD SP.ADR/65 (OK10) Stock Price Chart — Daily History & Trading Volume
The chart below tracks OKYO PHARMA LTD SP.ADR/65's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
OKYO PHARMA LTD SP.ADR/65 Income Statement — Revenue, Profit & Earnings by Year
OKYO PHARMA LTD SP.ADR/65's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | €0.00 | €0.00 | €0.00 | €0.00 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Research & Development | €2.25 Million | €8.24 Million | €6.34 Million | €1.61 Million |
| SG&A | — | — | — | — |
| Total Operating Expenses | €7.09 Million | €15.75 Million | €13.19 Million | €6.22 Million |
| Operating Income | €-7.09 Million | €-15.75 Million | €-13.19 Million | €-6.22 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €870.28K | €1.05 Million | €96.69K | €0.00 |
| Income Before Tax | €-7.97 Million | €-16.80 Million | €-13.28 Million | €-6.22 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €-4.71 Million | €-16.83 Million | €-13.27 Million | €-5.43 Million |
OKYO PHARMA LTD SP.ADR/65 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes OKYO PHARMA LTD SP.ADR/65's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | €3.68 Million | €1.54 Million | €5.20 Million | €4.30 Million |
| Total Current Assets | €3.68 Million | €1.54 Million | €5.20 Million | €4.30 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | €9.23 Million | €7.42 Million | €7.26 Million | €1.35 Million |
| Total Current Liabilities | €9.23 Million | €7.42 Million | €7.26 Million | €1.35 Million |
| Long-term Debt | — | — | — | — |
| Net Debt | — | — | — | — |
| Total Stockholder Equity | €-5.55 Million | €-5.88 Million | €-2.05 Million | €2.95 Million |
| Retained Earnings | €-143.02 Million | €-142.52 Million | €-125.70 Million | €-112.43 Million |
OKYO PHARMA LTD SP.ADR/65 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how OKYO PHARMA LTD SP.ADR/65 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | €-1.81 Million | €-9.49 Million | €-7.70 Million | €-5.47 Million |
| Capital Expenditures | €1.21K | €0.00 | €5.92K | €1.67K |
| Free Cash Flow | €-1.81 Million | €-9.49 Million | €-7.70 Million | €-5.47 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | €2.66 Million | €6.21 Million | €9.32 Million | €2.15 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | €734.99K | €1.12 Million | €1.29 Million | €1.74 Million |
| Depreciation | €2.56K | €3.87K | €3.80K | €2.33K |
| Change in Cash | €843.60K | €-3.28 Million | €1.62 Million | €-3.32 Million |
OKYO PHARMA LTD SP.ADR/65 Earnings History — EPS Actual vs. Analyst Estimates
Track OKYO PHARMA LTD SP.ADR/65's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 10, 2026 | — | — | — |
| Dec 22, 2025 | — | — | — |